Expert Opinion on Drug Safety,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 9
Published: Feb. 8, 2025
Background
Approved
by
the
FDA
in
2021,
varenicline
solution
is
first
nasal
spray
specifically
designed
to
enhance
basal
tear
film
production
for
treating
dry
eye
disease
(DED).
However,
there
a
lack
of
data
comprehensively
comparing
its
safety
profile
conventional
DED
therapies.
Herein,
we
assess
whether
ocular
adverse
events
(AEs)
are
disproportionately
reported
with
real-world
use
solution.
Heliyon,
Journal Year:
2025,
Volume and Issue:
11(2), P. e41881 - e41881
Published: Jan. 1, 2025
Anterior
eye
disorders
including
dry
syndrome,
keratitis,
chemical
burns,
and
trauma
have
varying
prevalence
rates
in
the
world.
Classical
dosage
forms
based-topical
ophthalmic
drugs
are
popular
treatments
for
managing
corneal
diseases.
However,
current
of
ocular
can
be
associated
with
major
challenges
such
as
short
retention
time
presence
barriers.
Developing
alternative
therapeutic
methods
is
required
to
overcome
drug
bioavailability
from
Nanocarriers
platforms
promising
candidates
administration
an
adjustable
manner.
This
paper
briefly
introduces
advantages,
disadvantages,
characteristics
delivery
systems
treatment
Additionally,
advanced
technologies
3D
printing
being
considered
fabricate
carriers
determine
dosages
personalized
treatment.
comprehensive
review
gathered
through
multiple
databases
Google
Scholar,
PubMed,
Web
Science.
It
explores
information
around
"ocular
systems'',
"nano-based
"engineered
nanocarriers'',
"advanced
systems''.
Journal of Nanobiotechnology,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: May 8, 2024
Abstract
Efficiently
removing
excess
reactive
oxygen
species
(ROS)
generated
by
various
factors
on
the
ocular
surface
is
a
promising
strategy
for
preventing
development
of
dry
eye
disease
(DED).
The
currently
available
drops
DED
treatment
are
palliative,
short-lived
and
frequently
administered
due
to
short
precorneal
residence
time.
Here,
we
developed
nanozyme-based
exploiting
borate-mediated
dynamic
covalent
complexation
between
n-FeZIF-8
nanozymes
(n-Z(Fe))
poly(vinyl
alcohol)
(PVA)
overcome
these
problems.
resultant
formulation
(PBnZ),
which
has
dual-ROS
scavenging
abilities
prolonged
corneal
retention
can
effectively
reduce
oxidative
stress,
thereby
providing
an
excellent
preventive
effect
alleviate
DED.
In
vitro
in
vivo
experiments
revealed
that
PBnZ
could
eliminate
ROS
through
both
its
multienzyme-like
activity
ROS-scavenging
borate
bonds.
positively
charged
displayed
longer
time
physical
adhesion
bonds
phenyboronic
acid
PVA
or
o-diol
with
mucin.
results
showed
These
dual-function
provide
insights
into
novel
strategies
other
ROS-mediated
inflammatory
diseases
rationale
application
nanomaterials
clinical
settings.
Graphical
Antioxidants,
Journal Year:
2024,
Volume and Issue:
13(1), P. 120 - 120
Published: Jan. 18, 2024
Diabetes
mellitus,
the
most
prevalent
endocrine
disorder,
not
only
impacts
retina
but
also
significantly
involves
ocular
surface.
contributes
to
development
of
dry
eye
disease
and
induces
morphological
functional
corneal
alterations,
particularly
affecting
nerves
epithelial
cells.
These
changes
manifest
as
defects,
reduced
sensitivity,
delayed
wound
healing,
collectively
encapsulated
in
context
diabetic
keratopathy.
In
advanced
stages
this
condition,
progression
ulcers
scarring
further
unfolds,
eventually
leading
opacities.
This
critical
complication
hampers
vision
carries
potential
for
irreversible
visual
loss.
The
primary
objective
review
article
is
offer
a
comprehensive
overview
pathomechanisms
underlying
Emphasis
placed
on
exploring
redox
molecular
pathways
responsible
aberrant
structural
observed
cornea
tear
film
during
diabetes.
Additionally,
we
provide
insights
into
latest
experimental
findings
concerning
treatments
targeting
oxidative
stress.
endeavor
aims
enhance
our
understanding
intricate
interplay
between
diabetes
complications,
offering
valuable
perspectives
future
therapeutic
interventions.
Biopolymers,
Journal Year:
2024,
Volume and Issue:
115(4)
Published: April 5, 2024
Ocular
drug
delivery
is
constrained
by
anatomical
and
physiological
barriers,
necessitating
innovative
solutions
for
effective
therapy.
Natural
polymers
like
hyaluronic
acid,
chitosan,
gelatin,
alongside
synthetic
counterparts
such
as
PLGA
PEG,
have
gained
prominence
their
biocompatibility
controlled
release
profiles.
Recent
strides
in
polymer
conjugation
strategies
enabled
targeted
through
ligand
integration,
facilitating
tissue
specificity
cellular
uptake.
This
versatility
accommodates
combined
delivery,
addressing
diverse
anterior
(e.g.,
glaucoma,
dry
eye)
posterior
segment
macular
degeneration,
diabetic
retinopathy)
afflictions.
The
review
encompasses
an
in-depth
exploration
of
each
natural
polymer,
detailing
individual
advantages
disadvantages
ocular
delivery.
By
transcending
barriers
refining
therapeutic
precision,
these
innovations
promise
to
reshape
the
management
eye
diseases.
International Journal of Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
658, P. 124192 - 124192
Published: May 3, 2024
Ocular
delivery
is
the
most
challenging
aspect
in
field
of
pharmaceutical
research.
The
major
hurdle
for
controlled
drugs
to
eye
includes
physiological
static
barriers
such
as
complex
layers
cornea,
sclera
and
retina
which
restrict
drug
from
permeating
into
anterior
posterior
segments
eye.
Recent
years
have
witnessed
inventions
conventional
nanocarrier
shown
considerable
enhancement
delivering
small
large
molecules
across
dynamic
challenges
associated
with
systems
include
limited
contact
time
inadequate
ocular
bioavailability
resulting
solution
drainage,
tear
turnover,
dilution
or
lacrimation.
To
this
end,
various
bioactive-based
nanosized
carriers
including
liposomes,
ethosomes,
niosomes,
dendrimer,
nanogel,
nanofibers,
lenses,
nanoprobes,
selenium
nanobells,
nanosponge,
polymeric
micelles,
silver
nanoparticles,
gold
nanoparticles
among
others
been
developed
circumvent
limitations
dosage
forms.
These
nanocarriers
achieve
enhanced
permeation
retention
prolong
release
tissue
due
their
better
adherence.
surface
charge
size
(10–1000
nm)
are
important
key
factors
overcome
barriers.
Various
deliver
active
therapeutic
timolol
maleate,
ampicillin,
natamycin,
voriconazole,
cyclosporine
A,
dexamethasone,
moxifloxacin,
fluconazole
treatment
diseases.
Taken
together,
a
nutshell,
book
chapter
provides
comprehensive
perspective
on
numerous
facets
special
focus
bioactive
nanocarrier-based
approaches,
difficulties
constraints
involved
fabrication
nanocarriers.
This
also
detailed
invention
applications
ophthalmic
therapeutics.
Small Structures,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 11, 2024
Topical
instillation
of
cyclosporin
A
(an
anti‐inflammatory
drug)
is
clinically
recommended
as
the
first‐line
treatment
for
dry
eye
disease.
Nevertheless,
it
suffers
from
poor
ocular
drug
retention
and
cannot
comprehensively
address
corneal
dryness‐related
symptoms
such
oxidative
stress,
angiogenesis,
neurodegeneration.
Inspired
by
nanotechnology‐mediated
material/biological
interactions,
in
this
study,
a
highly
adhesive
metallic
nanoplatform
with
an
urchin‐like
structure
designed
topical
quercetin
administration
therapy.
The
gold
nanostructures
most
pronounced
branch
lengths
exhibit
strongest
cytoadhesion
bioadhesion
capabilities,
which
significantly
enhance
nano‐urchins
150‐fold
at
7
days
post‐instillation
compared
smooth‐surfaced
nanoparticles.
In
rabbit
model
dryness,
single‐dose
nanoformulation
(high
quercetin‐functionalized
(NU‐Q(H)))
demonstrated
remarkable
efficacy
stimulating
tear
production
(30‐fold
improvement),
inhibiting
inflammatory
IL‐6
expression
(49‐fold
attenuating
pathological
angiogenesis
(32‐fold
promoting
nerve
regeneration
(18‐fold
improvement)
to
high
nanoparticles
(NP‐Q(H)).
particular,
integrity
surface,
film,
meibomian
gland
restored
levels
similar
those
healthy
rabbits.
These
findings
suggest
promising
potential
nanobiomaterial
structural
engineering
developing
nanomedicines
long‐acting
eye‐drop
formulations
disease
applications.
Journal of Nanobiotechnology,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: May 9, 2024
Abstract
Background
Dry
Eye
Disease
(DED)
is
a
prevalent
multifactorial
ocular
disease
characterized
by
vicious
cycle
of
inflammation,
oxidative
stress,
and
mitochondrial
dysfunction
on
the
surface,
all
which
lead
to
DED
deterioration
impair
patients’
quality
life
social
functioning.
Currently,
anti-inflammatory
drugs
have
shown
promising
efficacy
in
treating
DED;
however,
such
are
associated
with
side
effects.
The
bioavailability
less
than
5%
owing
factors
as
rapid
tear
turnover
presence
corneal
barrier.
This
calls
for
investigations
overcome
these
challenges
drug
administration.
Results
A
novel
hierarchical
action
liposome
nanosystem
(PHP-DPS@INS)
was
developed
this
study.
In
terms
delivery,
PHP-DPS@INS
nanoparticles
(NPs)
overcame
surface
transport
barrier
adopting
strategy
“ocular
electrostatic
adhesion-lysosomal
site-directed
escape”.
therapy,
achieved
targeting
antioxidant
effects
through
SS-31
peptide,
exerted
an
effect
loading
insulin
reduce
inflammatory
metabolites.
Ultimately,
synergistic
“anti-inflammation-antioxidation-mitochondrial
function
restoration”
breaks
DED.
demonstrated
remarkable
cellular
uptake,
lysosomal
escape,
vitro.
Targeted
metabolomics
analysis
revealed
that
effectively
normalized
elevated
level
proinflammatory
metabolite
fumarate
vitro
hypertonic
model
DED,
thereby
reducing
levels
key
(IL-1β,
IL-6,
TNF-α).
Additionally,
strongly
inhibited
reactive
oxygen
species
(ROS)
production
facilitated
structural
repair.
vivo,
treatment
significantly
enhanced
adhesion
duration
permeability
mice,
improving
bioavailability.
It
also
restored
secretion,
suppressed
damage,
reduced
inflammation
mice.
Moreover,
it
favorable
safety
profiles
both
vivo.
Conclusion
summary,
study
successfully
comprehensive
management
transmission
disrupted
dry
eye
pathogenesis.
pioneered
regulation
metabolites
conditions,
presenting
safe,
efficient,
innovative
therapeutic
other
diseases.